1 recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Recruiting 1 |
Follow R.Bos: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) Filgotinib, Anti-Tumor Necrosis Factor Alpha Drug (Product), 50 patients will have a Free Choice between Filgotinib and anti TNF - Rheumatoid Arthritis | Phase 4 | Recruiting | R.Bos | 100 | 2021-05-12 | 2025-08-08 |
Adalimumab (1) · Etanercept (1) · GLPG0634 (1) · Pharmaceutical Preparations (1)
Netherlands (1)